References
- 1. WHO classification of Tumours of Haematopoetic and Lymphoid Tissues 4th Edition:88
- 2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997; 89(6):2079-2088.
- 3. Schanz J, Tüchler H, Solé F, et al. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. J Clin Oncol, 2012: 30(8): 820-829.
- 4. Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer, 2010; 116(9):2174-2179.
- 5. https://www.ema.europa.eu/en/documents/product-information/vidaza-epar-product-information_en.pdf
- 6. Silverman LR, Demakos EP, Peterson BL, et al. Ranomized controlled trial of azacitidine in patients with the myelodys-plastic syndrome: a study of the cancer andl eukemia group B. J ClinOncol. 2002; 20(10):2429-40.
- 7. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-32.
- 8. Santini V, Melnick A, Maciejewski JP, et al. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. CritRevOn col Hematol. 2013;88(2):231-45.
- 9. Cheson BD, Greenberg P, Bennett JM, et al. Clinical application and proposal for modification of the Inter national Working Group (IWG) response criteria in myelodysplasia. Blood,. 2006;108(2):419-425.
- 10. Genova M, Grudeva-Popova J, Gercheva-Kiuchukova L, et al. Guide for the diagnosis and treatment of hematological diseases. Bulgarian Medical Society of hematology, Art Tracer, Varna 2018: ISBN 978-619-7094-39-8: 215-232.
- 11. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with>30% blasts. Blood. 2015;126(3):291-9.
- 12. Micheva I, Gerov V, Dimitrova S, et al. Outcome after azaciti-dine treatmentinpatients with high-risk myelodysplastic syndrome and acute myeloid leukemia in the Clinic of Hematology at St. Marina University Hospital, Varna. Scripta Scientifica Medica, 2017; 50 (1): 31-35.